[Erythropoetin and iron preparations in the treatment of anemia in patients with chronic kidney disease of stage III-IV in systemic diseases].
OBJECTIVE
To study efficacy and safety of long-term administration of epoetin and iron preparations in glomerulonephritis (GN) patients with chronic kidney disease (CKD) of stage III-IV in systemic diseases.


METHODS
A total of 189 patients at predialysis stage of CKD (glomerular filtration rate between 15 and 60 ml/min) were randomized into 3 groups depending on GN etiology: primary GN (group 1, 123 patients), GN in systemic diseases (group 2, 45 patients), controls (group 3, 21 patients). Anemia was characterized not only by red cells indices but also by the level of serum ferritin, C-reactive protein (CRP), saturation of transferrin with iron. Remodeling of the heart was determined in all the patients at dopplerechocardiography estimating left ventricular myocardial mass, relative thickness of its wall.


RESULTS
Correction of anemia was achieved in all the patients with GN and CKD of stage III-IV in systemic diseases despite the activity of systemic disease (high blood level of CRP) and persistent nephritis activity (high proteinuria). In many patients from groups 1 and 2 who were initially diagnosed to have left ventricular hypertrophy (LVH) of excentric type LVH regressed after 6 months of anemia correction. In group 3 with untreated anemia frequency of LVH increased.


CONCLUSIONS
Treatment of anemia in GN patients with CKD of stage III-IV in systemic diseases needed higher doses of epoetin and parenteral iron preparations compared to patients with the above stages of CKD with primary GN.
L V
LV
Kozlovskaia
Iu S
IuS
Milovanov
A Iu
AIu
Nikolaev
L Iu
LIu
Milovanova
D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002097:C-Reactive Protein / Q000378:metabolism; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D015150:Echocardiography, Doppler; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications* / Q000000981:diagnostic imaging / Q000503:physiopathology; D007501:Iron / Q000097:blood; D058085:Iron Compounds / Q000008:administration & dosage*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D008297:Male; D011994:Recombinant Proteins; D012720:Severity of Illness Index; D016896:Treatment Outcome
D006397:Hematinics; D006454:Hemoglobins; D058085:Iron Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D002097:C-Reactive Protein; D005293:Ferritins; D007501:Iron